DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer

Pathobiology

Volumn 73, Issue 2, 2006, Pages 63-70

  Pinto, António E ^a   André, Saudade ^a   Pereira, Teresa ^a   Silva, Giovani ^b   Soares, Jorge ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Adjuvant therapy; DNA ploidy; Node negative breast cancer; S phase fraction; Telomerase activity

Indexed keywords

BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TELOMERASE;

ADJUVANT THERAPY; ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST CANCER; CANCER STAGING; CELL CYCLE S PHASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PLOIDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; S PHASE; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 33748266669     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094490     Document Type: Article

References (33)

1. Clark RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, Lipa M, Wilkinson RH, Mahoney LJ: Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update. Ontario Clinical Oncology Group. J Natl Cancer Inst 1996;88:1659-1664.
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn H-J, Panel Members: Meetings highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
3. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
4. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992;326:1756-1761.
5. Hortobagyi GN: Adjuvant systemic therapy for early breast cancer: progress and controversies. Clin Cancer Res 2001;7:1839-1842.
6. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878.
7. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW: Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst 1997;89:1874-1881.
8. Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schaefer K-L, Braun Y, Schuck A, Lanvers C, Bankfalvi A, Kneif S, Torhorst J, Zuber M, Kochli OR, Mross F, Dieterich H, Sauter G, Stein H, Fogt F, Boecker W: Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray of hTERT and hTR. J Pathol 2002;198:181-189.
9. Hahn WC: Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003;21:2034-2043.
10. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.
11. Sobin LH, Wittekind Ch (eds): UICC TNM classification of malignant tumours, 6th ed. New York: John Wiley and Sons, Inc., 2002.
12. Pinto AE, André S, Soares J: Short term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol 1999;52:604-611.
13. Stanton PD, Cooke TG, Oakes SJ, Winstanley J, Holt S, George WD, Murray GD: Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. Br J Cancer 1992;66:925-929.
14. Bergers E, Baak JPA, van Diest PJ, Willig AJP, Los J, Peterse JL, Ruitenberg HM, Schapers RFM, Somsen JG, van Beek MWPM, Bellot SM, Fijnheer J, van Gorp LHM: Prognostic value of DNA ploidy using flow cytometry in 1301 breast cancer patients: results of the prospective multicenter morphometric mammary carcinoma project. Mod Pathol 1997;10:762-768.
15. Prasad AR, Divine G, Zarbo RJ: Two-color, cytokeratin-labeled DNA flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up. Arch Pathol Lab Med 2001;125:364-374.
16. Malmström P, Bendahl P-O, Boiesen P, Brünner N, Idvall I, Fernö M for the South Sweden Breast Cancer Group: S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham prognostic index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001;19:2010-2019.
17. Michels J-J, Marnay J, Delozier T, Denoux Y, Chasle J: Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer 2004;100:455-464.
18. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA, for the International Breast Cancer Study Group: Ki67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer 2003;97:1321-1331.
19. Buys CHCM: Telomeres, telomerase, and cancer. N Engl J Med 2000;342:1282-1283.
20. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Pirtyszek MA, Shay JW: Telomarase activity in human breast cancers. J Natl Cancer Inst 1996;88:116-122.
21. Baykal A, Rosen D, Zhou C, Liu J, Sahin AA: Telomerase in breast cancer. A critical evaluation. Adv Anat Pathol 2004;11:262-268.
22. Mokbel K, Parris CN, Radbourne R, Ghilchik M, Newbold RF: Telomerase activity and prognosis in breast cancer. Eur J Surg Oncol 1999;25:269-272.
23. Carey LA, Kim NW, Goodman S, Marks J, Henderson G, Umbricht CB, Dome JS, Dooley W, Amshey SR, Sukermar S: Telomerase activity and prognosis in primary breast cancers. J Clin Oncol 1999;17:3075-3081.
24. Nawaz S, Hashizumi TL, Markham NE, Shroyer AL, Shroyer KR: Telomerase expression in human breast cancer with and without lymph node metastases. Am J Clin Pathol 1997;107:542-547.
25. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991;6:137-143.
26. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-443.
27. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases. Breast Cancer Res Treat 1995;35:283-291.
28. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J: The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 2000;88:804-813.
29. Rudolph P, Olsson H, Bonatz G, Ratjen V, Boite H, Baldetorp B, Ferno M, Parwaresch R, Alm P: Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999;187:207-216.
30. Pinto AE, André S, Pereira T, Nóbrega S, Soares J: c-erbB-2 oncoprotein expression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol 2001;12:525-533.
31. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL: The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 2004;22:86-96.
32. Volpi A, Nanni O, De Paola F, Granato AM, Mangia A, Monti F, Schittulli F, De Lena M, Scarpi E, Rosetti P, Monti M, Gianni L, Amadori D, Paradiso A: HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol 2003;21:2708-2712.
33. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462-469.